Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA single-center review of 200 cancer patients taking a GLP-1 drug alongside platinum chemotherapy found upper-gut side effects in nearly two-thirds, mostly mild and manageable. With no comparison group, the scarier mortality gap reflects who was sicker, not what the drug did.
In a TriNetX records study, people on tirzepatide had 18 to 25 percent lower carpal tunnel risk than users of other weight drugs. The authors called it neuroprotective. The plainer reading is that a wrist under less weight has more room for the nerve.
A Japanese claims study of nearly 300,000 people with type 2 diabetes found GLP-1 drugs carried no higher risk of a blocked or paralyzed bowel than an SGLT2 comparator. The null rules out a large effect, not a small one.
A German team aimed an off-the-shelf peptide vaccine at the EWSR1-FLI1 fusion junction that drives Ewing sarcoma. The patient built durable T-cell immunity and stayed stable past 26 months. It is also a study of exactly one person.
A SELECT trial reanalysis showed semaglutide slowing a 25-protein blood score that predicts dementia risk. A Taiwan cohort found fewer diagnoses on GLP-1 drugs, but only in the vaguest category. Two studies, same day, and the gap between them is the story.
A designed peptide, WMX-8, plugged IL17RA and matched an approved anti-inflammatory antibody in cultured skin and immune cells. There is no animal or human data, and the oral, cheaper pitch behind it is untested.
A generative-AI pipeline (RFDiffusion, ProteinMPNN, AlphaFold2) designed a peptide, SCP-1, built to lock the immune sensor STING in its inactive shape. Delivered in an enzyme-responsive gel, it calmed chronic inflammation and sped healing of diabetic wounds in mice. It is a preclinical, locally delivered result with no human data.
A synthetic peptide, aMPC16-CA50, ruptures tumor cells in two pH-triggered steps, damaging the lysosome first and the outer membrane later. The lag makes the death immunogenic, and in mice the peptide made immune-checkpoint drugs work better. It is cell-and-mouse work, published in Nature, with no human data yet.
A GLP-1 drug widened the blood supply to insulin-making islets within minutes, but only in diabetic mice and only when nitric oxide was available, pointing to a weight-independent way the drug may help beta cells.
The economist behind the 2005 trust-hormone experiment returned with a large preregistered study. Oxytocin lifted trust about 15 percent, but only in men low in the disposition to trust.
A single amino-acid change in the GLP-1 receptor tracked slower beta-cell decline over 20 years and a modestly better response to GLP-1 drugs, a candidate genetic marker for who benefits most.
In healthy volunteers the GLP-1 drug liraglutide cut plasma vasopressin, and animal work traced the effect up to the brain and down to the kidney's aquaporin-2 water channel, with sex-dependent steps.
Dual GLP-1 and glucagon drugs protect the kidney, and a new mouse-and-human study says the glucagon half does it directly, by keeping a lysosomal proton pump clicked together inside tubule cells.
A Yale and Manchester study in female mice found that AgRP hunger neurons, long assumed to be switched off by GLP-1 drugs, are actually required for the drugs' full weight loss.
A 600,000-patient records study found that among people with type 2 diabetes on GLP-1 drugs, cannabis users had substantially higher death, heart, and kidney risk, dose-dependently. The honest read is a risk marker, not proof the drug fails or that cannabis is the cause.